Diagnosis and Treatment of Mirizzi Syndrome: 23-Year Mayo Clinic Experience

被引:75
|
作者
Erben, Young [1 ]
Benavente-Chenhalls, Luis A. [1 ]
Donohue, John M. [1 ]
Que, Florencia G. [1 ]
Kendrick, Michael L. [1 ]
Reid-Lombardo, Kaye M. [1 ]
Farnell, Michael B. [1 ]
Nagorney, David M. [1 ]
机构
[1] Mayo Clin, Div Gastroenterol & Gen Surg, Rochester, MN 55905 USA
关键词
LAPAROSCOPIC CHOLECYSTECTOMY; PREOPERATIVE DIAGNOSIS; CLASSIFICATION; FISTULA;
D O I
10.1016/j.jamcollsurg.2011.03.008
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: Mirizzi syndrome (MS) is characterized by extrinsic compression of the common hepatic duct by stones impacted in the cystic duct or gallbladder neck. Open cholecystectomy (OC) has been the standard treatment; however, laparoscopy has challenged this approach. STUDY DESIGN: The objective of this study was to review our clinical experience with MS since the introduction of laparoscopic cholecystectomy (LC) and determine the impact of alternative approaches. We conducted a retrospective review of patients with MS from January 1987 to December 2009. RESULTS: There were 36 patients with MS among 21,450 cholecystectomies (frequency 0.18%). Seventeen were women. The most common presenting symptoms were abdominal pain (n = 23) and jaundice (n = 19). Preoperative diagnostic studies included ultrasonography (n = 27), CT (n = 24), and endoscopic retrograde cholangiopancreatography (n = 32). Cholecystectomy was performed in 35 patients; LC was initiated in 15 and OC in 21. Conversion rate from LC to OC was 67%. Five patients who had successful LC had type I MS. Of the patients who underwent LC with conversion or OC, 14 had type I and 16 had type II MS. The cystic duct for type I and the bile duct for type II MS were managed diversely according to surgeon's preference. There was no operative mortality. Morbidity was 31% with Clavien class I in 2, IIIa in 4, IIIb in 1, and IV in 3 patients. Mean hospitalization was 9 days (range 2 to 40 days). Mean follow-up was 37 months (range 1 to 187 months). CONCLUSIONS: Low incidence and nonspecific presentation of MS precludes referral and substantive individual experience. Although LC may be applicable in selected patients with type IMS, OC remains the standard of care. (J Am Coll Surg 2011; 213: 114-121. (C) 2011 by the American College of Surgeons)
引用
收藏
页码:114 / 119
页数:6
相关论文
共 50 条
  • [31] Adrenal hemorrhage: A 25-year experience at the Mayo Clinic
    Vella, A
    Nippoldt, TB
    Morris, JC
    MAYO CLINIC PROCEEDINGS, 2001, 76 (02) : 161 - 168
  • [32] Acute cortical necrosis: 25 year Mayo clinic experience
    Murali, NS
    Ghosh, AK
    Grande, JP
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (04) : A27 - A27
  • [33] Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience
    K Begna
    A Abdelatif
    S Schwager
    C Hanson
    A Pardanani
    A Tefferi
    Blood Cancer Journal, 2016, 6 : e427 - e427
  • [34] Total Lymphoid Irradiation in The Treatment and Prevention of Pediatric Cardiac Allograft Rejection - A 23-Year Experience
    Hsieh, K.
    Yan, S. X.
    Jain, A. K.
    Horowitz, D. P.
    Wang, T. J. C.
    Wu, C. C.
    Connolly, E. P.
    Addonizio, L.
    Cheng, S. K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E229 - E229
  • [35] Treatment of lichen sclerosus with hydroxychloroquine: a Mayo Clinic experience
    Akpala, Christeebella O.
    Tekin, Burak
    Torgerson, Rochelle R.
    Wetter, David A.
    Nguyen, Giang Huong
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2024, 63 (10) : e240 - e243
  • [36] Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience
    Begna, K.
    Abdelatif, A.
    Schwager, S.
    Hanson, C.
    Pardanani, A.
    Tefferi, A.
    BLOOD CANCER JOURNAL, 2016, 6 : e427 - e427
  • [37] Neostigmine for the treatment of colonic pseudoobstruction - The Mayo clinic experience
    Loftus, CG
    Harewood, GC
    Baron, TH
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (09): : S111 - S111
  • [38] Busulfan for the Treatment of Myeloproliferative Neoplasms: The Mayo Clinic Experience
    Begna, Kebede H.
    Abdelatif, Amro
    Schwager, Susan M.
    Hanson, Curtis A.
    Pardanani, Animesh
    Tefferi, Ayalew
    BLOOD, 2015, 126 (23)
  • [39] Budesonide in the treatment of inflammatory bowel disease: A one year experience in clinical practice at the Mayo clinic
    Chopra, A
    Lothis, EV
    Tremaine, WJ
    Egan, LJ
    Faubion, WA
    Pardi, DS
    Hanson, KA
    Johnson, TA
    Sandborn, WJ
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (10): : S247 - S247
  • [40] Mortality in Hypereosinophilic Syndrome: Ten Years of Experience at Mayo Clinic
    Podjasek, J.
    Butterfield, J.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) : AB207 - AB207